Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

OBJECTIVE In schizophrenia, cognitive dysfunctions commonly affect attention, memory and executive function, interfere with functional outcome and remain difficult to treat. Previous studies have implicated the cholinergic system in cognitive functioning. In Alzheimer's disease, cholinergic agonists have shown modest clinical benefits on cognitive and behavioural symptoms. Impaired cholinergic activity might also be involved in schizophrenia. Hence the role of cholinesterase inhibitors (ChEI) as adjunctive therapy is under study. We aimed to review the literature and evaluate the overall effectiveness of ChEI adjunctive therapy for the management of cognitive dysfunctions in schizophrenia. METHODS We conducted a computer-based search using PubMed (up to February 15, 2006) and ISI Web of Science (conference proceeding abstracts from January 2003 to December 2005) databases. We used the search terms "schizophrenia," "cognition or memory" and "tacrine or donepezil or rivastigmine or galantamine." Studies included were critically analyzed for allocation, blindness, duration and study design, demographic data, and clinical and neuropsychological outcome assessments. We excluded studies that involved patients with psychiatric disorders other than schizophrenia-spectrum or if they involved animals or molecular investigations. We also excluded conference proceeding abstracts with no explicit neuropsychological battery and/or results. RESULTS Data on ChEI as adjunctive therapy for the cognitive impairments in schizophrenia are sparse and so far derived from small samples and mostly open uncontrolled studies. ChEI's potential in long-term management has barely been documented and remains to be fully explored. CONCLUSION There is insufficient evidence on whether ChEI should be used for the treatment of cognitive dysfunctions in schizophrenia. Nevertheless, further studies with appropriate trial designs and outcome measures in homogenous schizophrenia populations are warranted.

[1]  D. Paleacu,et al.  Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study , 2006, International Psychogeriatrics.

[2]  M. Freedman,et al.  Progress in Clinical Neurosciences: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary , 2006, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[3]  S. Gauthier.  Alzheimer's disease: the benefits of early treatment , 2005, European journal of neurology.

[4]  T. Sharma,et al.  Effects of Rivastigmine on Sustained Attention in Schizophrenia: An fMRI Study , 2005, Journal of clinical psychopharmacology.

[5]  D. Palumbo,et al.  Efficacy and Tolerability of Low-Dose Donepezil in Schizophrenia , 2005, Clinical neuropharmacology.

[6]  S. Goldstein.  Clinical Applications of Continuous Performance Tests: Measuring Attention and Impulsive Responding in Children and Adults , 2005 .

[7]  E. Bora,et al.  The Effect of Galantamine Added to Clozapine on Cognition of Five Patients With Schizophrenia , 2005, Clinical neuropharmacology.

[8]  S. Gauthier.  Drugs for Alzheimer's disease and related dementias , 2005, BMJ : British Medical Journal.

[9]  D. Goff,et al.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial , 2005, Psychopharmacology.

[10]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[11]  M. Kotler,et al.  Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living , 2004, International clinical psychopharmacology.

[12]  Michael F. Green,et al.  Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia , 2004, Schizophrenia Research.

[13]  Philip D. Harvey,et al.  The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.

[14]  A. E. A. Yağcıoğlu,et al.  A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. , 2004, The international journal of neuropsychopharmacology.

[15]  Enzo Poggi,et al.  Effects of Rivastigmine on Cognitive Function and Quality of Life in Patients With Schizophrenia , 2003, Clinical neuropharmacology.

[16]  Xingbao Li,et al.  Augmenting Atypical Antipsychotics with a Cognitive Enhancer (Donepezil) Improves Regional Brain Activity in Schizophrenia Patients: A Pilot Double-blind Placebo Controlled BOLD fMRI Study , 2003, Neurocase.

[17]  Martin Radina,et al.  Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  P. Fossier,et al.  Cholinergic modulation of the cortical neuronal network , 2003, Pflügers Archiv.

[19]  T. Sharma,et al.  Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. , 2003, The Psychiatric clinics of North America.

[20]  Robert W. Buchanan,et al.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia , 2003, Schizophrenia Research.

[21]  Abraham Weizman,et al.  Beneficial Effect of Donepezil Augmentation for the Management of Comorbid Schizophrenia and Dementia , 2003, Clinical neuropharmacology.

[22]  J. McEvoy,et al.  Galantamine for treatment-resistant schizophrenia. , 2002, The American journal of psychiatry.

[23]  M. Mesulam,et al.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.

[24]  Jin Dai,et al.  Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum , 2002, Neuropsychopharmacology.

[25]  Philip D. Harvey,et al.  A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia , 2002, Biological Psychiatry.

[26]  T. Hyde,et al.  Cholinergic systems and schizophrenia: primary pathology or epiphenomena? , 2001, Journal of Chemical Neuroanatomy.

[27]  B. Dean,et al.  Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. , 2001, The American journal of psychiatry.

[28]  C. Reynolds,et al.  Clinical Applications of Continuous Performance Tests: Measuring Attention and Impulsive Responding in Children and Adults , 2001 .

[29]  Philip D. Harvey,et al.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. , 2001, The American journal of psychiatry.

[30]  R. Freedman,et al.  The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia , 2000, Journal of Chemical Neuroanatomy.

[31]  K. Davis,et al.  Postmortem studies in schizophrenia , 2000, Schizophrenia bulletin.

[32]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[33]  Stephan Heckers,et al.  Schizophrenia and cognitive function , 2000, Current Opinion in Neurobiology.

[34]  A. Maelicke,et al.  Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. , 2000, European journal of pharmacology.

[35]  J. Brandt,et al.  Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. , 1999, The Clinical neuropsychologist.

[36]  R. Polinsky,et al.  Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 1998, Clinical therapeutics.

[37]  D. Michaelson,et al.  The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice , 1998, Journal of Physiology-Paris.

[38]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[39]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[40]  T. Robbins.  Arousal systems and attentional processes , 1997, Biological Psychology.

[41]  L Kruglyak,et al.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Reisberg,et al.  Mortality and Temporal Course of Probable Alzheimer's Disease: A 5-Year Prospective Study , 1996, International Psychogeriatrics.

[43]  R. J. Wyatt,et al.  An economic evaluation of schizophrenia-1991 , 1995, Social Psychiatry and Psychiatric Epidemiology.

[44]  E. Perry,et al.  Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness , 1995, Brain and Cognition.

[45]  R. Freedman,et al.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.

[46]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[47]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[48]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[49]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[50]  A. Hafkenscheid.  Reliability of a standardized and expanded Brief Psychiatric Rating Scale: a replication study , 1993, Acta psychiatrica Scandinavica.

[51]  W. J. Jackson,et al.  Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys , 1993, Pharmacology Biochemistry and Behavior.

[52]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[53]  J. Changeux,et al.  Allosteric modulations of the nicotinic acetylcholine receptor , 1993, Trends in Neurosciences.

[54]  R. Ihl,et al.  Differential validity of psychometric tests in dementia of the Alzheimer type , 1992, Psychiatry Research.

[55]  Jean Addington,et al.  Reliability and validity of a depression rating scale for schizophrenics , 1991, Schizophrenia Research.

[56]  J L McGaugh,et al.  The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory , 1991, Synapse.

[57]  N. Mimica,et al.  Scale for the Assessment of Negative Symptoms (SANS)* , 1989, British Journal of Psychiatry.

[58]  E. A. Burch,et al.  Comparison of Two Cognitive Rating Scales in Medically Ill Patients , 1988, International journal of psychiatry in medicine.

[59]  B. Cornblatt,et al.  Auditory recognition memory in adolescents at risk for schizophrenia: Report on a verbal continuous recognition task , 1980, Psychiatry Research.

[60]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[61]  S. Snyder,et al.  Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. , 1974, Archives of general psychiatry.

[62]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[63]  D. A. Grant,et al.  A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem. , 1948, Journal of experimental psychology.

[64]  W. Sturm,et al.  Neuropsychological assessment , 2007, Journal of Neurology.

[65]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[66]  J. Peuskens,et al.  Treatment of cognitive dysfunction in schizophrenia. , 2005, Clinical therapeutics.

[67]  Martin Sarter,et al.  Cortical cholinergic transmission and cortical information processing in schizophrenia. , 2005, Schizophrenia bulletin.

[68]  M. Lezak,et al.  Neuropsychological assessment, 4th ed. , 2004 .

[69]  Douglas W. Jones,et al.  In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. , 2003, The American journal of psychiatry.

[70]  B. Dean,et al.  Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia , 2002, Molecular Psychiatry.

[71]  J. Ridley.  Studies of Interference in Serial Verbal Reactions , 2001 .

[72]  T. Goldberg,et al.  Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.

[73]  C. E. Adams,et al.  The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. , 2000, Journal of chemical neuroanatomy.

[74]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[75]  D. Murphy,et al.  Cognitive and Behavioral Effects of Cholinergic, Dopaminergic, and Serotonergic Blockade in Humans , 1997, Neuropsychopharmacology.

[76]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[77]  N. Varney,et al.  Psychopharmacology: The Fourth Generation of Progress. , 1996 .

[78]  J. Lieberman,et al.  Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. , 1992, Schizophrenia bulletin.

[79]  J. Stroop.  Studies of interference in serial verbal reactions. , 1992 .

[80]  J. Kleinman,et al.  The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[81]  H. Barz,et al.  Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine , 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[82]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[83]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[84]  F. Baker,et al.  Quality of life in the evaluation of community support systems. , 1982, Evaluation and program planning.